All Oncology News

The European Medicines Agency (EMA) has received a Marketing Authorization Application (MAA) for tisagenlecleucel (Kymriah) for 2 forms of advanced lymphoma.

The FDA has approved alectinib (Alecensa) for the frontline treatment of patients with ALK-positive metastatic non-small cell lung cancer.

Paul Sabbatini, MD, discusses the recent data surrounding IP and dose-dense therapy and the next steps for both treatment approaches in ovarian cancer.

Mario M. Leitao, Jr, MD, FACOG, FACS, discusses how surgery retains its imperative role in ovarian cancer and sheds light on the challenges that still remain.

Clinical trials help community practices attract patients, inspire oncologists, and lower costs, but forming a program can be daunting to the uninitiated.

The FDA has approved vemurafenib as a treatment for patients with Erdheim-Chester disease.

The first annual Luminary Awards in GI Cancers honoring five outstanding individuals who have devoted their time, talent and resources to improving the care for patients and families affected by GI cancers, will be presented Friday, Dec. 1 at the 8th Annual Ruesch Center Symposium: Fighting a Smarter War on Cancer in Washington.

In phase Ib results from the KEYNOTE-028 trial, pembrolizumab (Keytruda) was found to be active in cervical cancer while demonstrating safety results similar to previous studies with the PD-1 inhibitor.

Alfred L. Garfall, MD, MS, discussed the treatment and management of patients with multiple myeloma, with a focus on maintenance therapy, CAR T-cell therapy, and the role of transplant.

According to phase III results from the FOLL05 trial, the combination of rituximab plus cyclophosphamide, vincristine, and prednisone produced survival results comparable with standard-of-care regimens in patients with advanced symptomatic follicular lymphoma.

Edward A. Stadtmauer, MD, sheds light on the future of chimeric antigen receptor T-cell therapy, systemic therapeutic advances in the field of acute myeloid leukemia, and remaining challenges in the multiple myeloma paradigm.

A supplemental new drug application has been submitted for brentuximab vedotin in combination with Adriamycin, vinblastine, dacarbazine as a frontline treatment for advanced classical Hodgkin lymphoma.

Pexidartinib met its primary endpoint of tumor response as measured by tumor size reduction in patients with symptomatic tenosynovial giant cell tumor where surgical resection is contraindicated.

The FDA has granted GSK2857916 a breakthrough therapy designation for patients with relapsed/refractory multiple myeloma.

Mary Jo Fidler, MD, discusses targeting the EGFR-gene activating mutations, first- and second-generation inhibitors, and the potential of osimertinib.

Patients with peripheral T-cell lymphoma are more likely to have superior overall survival if they have previously demonstrated event-free survival at 24 months.

More than half of elderly, treatment-naïve patients with AML assigned to treatment with guadecitabine had a composite complete response irrespective of dosage or schedule.

A newly announced CMS policy to redistribute savings under the 340B Drug Discount Program so that Medicare beneficiaries save money on copayments has garnered a mixture of praise and criticism from supporters and critics of the program.

The UK’s National Institute for Health and Care Excellence is recommending the use of atezolizumab for treatment-naïve patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-based therapy.

Michael A. Postow, MD, discusses the impressive efficacy seen with combining BRAF and MEK inhibitors for patients with melanoma.

Laura J. van’t Veer, PhD, discusses determining more accurate methods of treatment for patients with early- and late-state breast cancer based on advances in genetic testing, specifically the 70-gene prognostic signature.

David G. Maloney, MD, PhD, discusses the progress made with CAR T cells, as well as the challenges that still exist in the use of this therapy.

The FDA has granted an accelerated approval to acalabrutinib as a treatment for adult patients with mantle cell lymphoma following at least 1 prior therapy.

Novartis has filed a supplemental biologics license application with the FDA to expand the indication for tisagenlecleucel (Kymriah) to include adults with relapsed/refractory DLBCL who are ineligible for ASCT.

Michelle E. Melisko, MD, discusses a variety of pivotal trials with adjuvant hormonal therapy and other developments in the treatment of patients with ER-positive breast cancer.

Elizabeth Plimack, MD, discusses the management of locally advanced urothelial carcinoma and the ongoing trials that are investigating treatments for this patient population.

Elizabeth A. Mittendorf, MD, PhD, discusses the evolving neoadjuvant treatment landscape and other developments in the field of HER2-postive breast cancer.

Merck has announced that it has withdrawn its European application for pembrolizumab in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non-small cell lung cancer.

Kathryn A. Gold, MD, discusses HPV status and prognosis, as well recognizing risk factors of virally-associated head and neck squamous cell carcinoma.

Novartis has announced a planned $3.9-billion acquisition of Advanced Accelerator Applications, a radiopharmaceutical company that develops, produces, and commercializes Molecular Nuclear Medicines.